Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5928772 | 0.80 | NPC1 (0.64) | NPC1SMN1; SMN2ATMLMNATSHR | |
| SCHEMBL3714715 | 0.80 | SMN1; SMN2 (0.71) | NPC1SMN1; SMN2ATMLMNATSHR | |
| SCHEMBL14743414 | 0.78 | SMN1; SMN2 (0.69) | NPC1SMN1; SMN2ATMLMNATSHR | |
| SCHEMBL3715629 | 0.76 | KDM4E (0.58) | NPC1SMN1; SMN2ATMLMNATSHR | |
| SCHEMBL30388095 | 0.76 | KDM4E (0.58) | NPC1SMN1; SMN2ATMLMNATSHR | |
| SCHEMBL28677827 | 0.76 | SMN1; SMN2 (0.62) | NPC1SMN1; SMN2ATMLMNATSHR | |
| SCHEMBL5928915 | 0.76 | NPC1 (0.72) | NPC1SMN1; SMN2ATMLMNATSHR | |
| SCHEMBL3766623 | 0.75 | NPC1 (1.00) | NPC1SMN1; SMN2ATMLMNATSHR | |
| SCHEMBL5928664 | 0.75 | SMN1; SMN2 (0.92) | NPC1SMN1; SMN2ATMLMNATSHR | |
| SCHEMBL1302793 | 0.72 | KDM4E (0.66) | NPC1SMN1; SMN2ATMLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609674-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2012067824-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122890-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122890-A1 | Potassium Channel Modulators | KCNQ1, KCNQ2, KCNQ3 | NPC1 712/4885SMN1; SMN2 1749/4885ATM 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.